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Abstract Alzheimer’s disease is the most prevalent neurodegenerative disorder leading to
progressive cognitive decline. Despite decades of research, understanding AD progression at the
molecular level, especially at its early stages, remains elusive. Here, we identified several
presymptomatic AD markers by investigating brain proteome changes over the course of
neurodegeneration in a transgenic mouse model of AD (3Tg-AD). We show that one of these
markers, heme-binding protein 1 (Hebp1), is elevated in the brains of both 3Tg-AD mice and
patients affected by rapidly-progressing forms of AD. Hebp1, predominantly expressed in neurons,
interacts with the mitochondrial contact site complex (MICOS) and exhibits a perimitochondrial
localization. Strikingly, wildtype, but not Hebp1-deficient, neurons showed elevated cytotoxicity in
response to heme-induced apoptosis. Increased survivability in Hebp1-deficient neurons is
conferred by blocking the activation of the mitochondrial-associated caspase signaling pathway.
Taken together, our data highlight a role of Hebp1 in progressive neuronal loss during AD
progression.
DOI: https://doi.org/10.7554/eLife.47498.001
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Introduction
Alzheimer’s disease is a progressive neurodegenerative disorder that leads to memory loss and cog-
nitive decline. It is the most prevalent form of dementia in the elderly and is projected to affect
more than 40 million people worldwide (GBD , Disease and Injury Incidence and Prevalence Col-
laborators et al., 2017). At the molecular level, AD is characterized by a disturbed metabolism of
amyloid beta (Ab) peptides that results in formation of toxic oligomers and insoluble aggregates
(plaques) in the brains of afflicted individuals (Selkoe and Hardy, 2016). AD pathology is also
accompanied by formation of neurofibrillary tangles comprising of hyperphosphorylated microtu-
bule-associated protein tau. Ab deposits and phospho-tau-containing neurofibrils serve as molecular
hallmarks of AD and are thus useful for histopathological diagnosis (Vinters, 2015). However, the
aggregation of Ab and tau alone does not fully account for the cognitive decline observed in AD
patients (Davis et al., 1999). Although mutations in amyloid precursor protein (APP) and its pro-
teases presenilin-1 and 2 have a causative relationship with the onset of familiar form of Alzheimer’s
disease (FAD), overt manifestation of clinical AD is often preceded by a prolonged incubation period
(Ryman et al., 2014). This leads to recognition of AD as a complex multifaceted disorder that
strongly depends on the intricate interplay between neuronal survival, synaptic function, activation
of glial cells, inflammatory response, blood-brain barrier impairment and other factors (De Strooper
and Karran, 2016). Nevertheless, the knowledge of the biological processes that are first affected in
AD remain limited. Identification of these processes will expand our understanding of early AD path-
ogenesis and may lay the ground for the development of more effective therapeutics in the future.
Changes in gene expression can be indicative of underlying physiological and pathological altera-
tions during disease progression. Indeed, studies utilizing cDNA microarray, RNA sequencing and
mass spectrometry approaches to analyze such changes in human postmortem brain tissue have
broadened our understanding of genes and proteins involved in AD (Alkallas et al., 2017;
Donovan et al., 2012; Mathys et al., 2017; Moya-Alvarado et al., 2016; Musunuri et al., 2014;
Podtelezhnikov et al., 2011). While such studies provide important insights into molecular pathol-
ogy at later stages, they offer limited information about prior alterations that occur over the course
of the development of the disorder. In particular, early changes in protein expression preceding the
clinical onset of the disease would be missed. Detection of such presymptomatic protein markers
would not only aid the earlier diagnosis of afflicted individuals but also potentially enable the identi-
fication of early targets for therapeutic intervention.
To identify such markers, we probed for temporal changes in the brain proteome of 3Tg-AD
transgenic mice that harbor three mutated genes associated with the disease (PSEN1 M146V, APP
Swe, MAPT (tau) P301L). These mice develop Alzheimer-related phenotypes in a progressive manner
mimicking the human disorder (Oddo et al., 2003a; Oddo et al., 2003b). Quantitative mass spec-
trometry was employed to compare the brain proteomes of 3Tg-AD transgenic mice against age-
matched controls at four time points corresponding to various stages of the disorder. Both age- and
disease-dependent alterations could be observed in the brain proteome of 3Tg-AD mice. Signifi-
cantly, the analyses further revealed several potential presymptomatic protein markers that are dif-
ferentially expressed between 3Tg-AD and control mice. One of these markers, heme-binding
protein-1 (Hebp1), is significantly elevated in the brains of both 3Tg-AD mice and human patients
exhibiting rapidly-progressing forms of AD. Hebp1 is primarily expressed in neurons where it is asso-
ciated with mitochondria via the MICOS complex. Functionally, Hebp1 mediates heme-induced cyto-
toxicity via an apoptotic pathway. Thus, it is of relevance both as an early marker and contributing
factor to the development of AD.
Results
Brain proteomes of wild-type and 3Tg-AD mice exhibit age- and
disease-related changes
To identify proteins involved in early stage AD, we monitored for changes in the brain proteomes of
control and 3Tg-AD mice at four different time points using label-free quantitative mass spectrom-
etry. These time points were selected according to the pathological changes in 3Tg-AD mice
based on previously published data (Hawkes et al., 2013; Oddo et al., 2003a; Wirths et al., 2012)
and our own observations (Figure 1—figure supplement 1). We included presymptomatic time
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point (2 months), the age of first behavioral abnormalities (6 months), appearance of first Ab plaques
and hyperphosphorylated tau (12–18 months) (Figure 1A). At the designated time points, one half
of the harvested brain from each animal was processed to obtain a soluble protein fraction that was
subjected to analyses by label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS)
Figure 1. Progression of Alzheimer’s disease at molecular level in the triple transgenic mouse model (PSEN1M146V/APPSwe/MAPTP301L). (A) Disease
progression in 3Tg-AD mice and corresponding time points (2, 6, 12, 18 months) of sample collection. Four biological replicates per group were
collected at each time point. (B) Experimental workflow and sample processing. Half of the collected brain sample was used for preparation of the
cryosections for immunohistochemistry. Soluble proteins of the other half were extracted for proteomics analysis. (C) Number of identified, quantified
and statistically significant proteins in the dataset. (D) Principal component analysis of soluble brain proteome of 3Tg-AD and control mice based on
their protein expression profile. Principal component one segregates mice by age and accounts for 40.3% of variability in the dataset, while principal
component two clusters mice according to their disease status (18.9% of variance). (E) Proteins driving the differences in proteomes between aged,
young, diseased and control mice depicted in brown, pink, navy and light blue colors, respectively.
DOI: https://doi.org/10.7554/eLife.47498.002
The following figure supplements are available for figure 1:
Figure supplement 1. Assessment of pathology in 3Tg-AD mice used in this study.
DOI: https://doi.org/10.7554/eLife.47498.003
Figure supplement 2. Technical reproducibility between biological replicates.
DOI: https://doi.org/10.7554/eLife.47498.004
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(Figure 1B). Cryosections were prepared from the other half of the brain for subsequent immunohis-
tochemical analyses of the hits identified by mass spectrometry.
Analysis of the datasets using MaxQuant software (Cox and Mann, 2008), applying a peptide
and protein false discovery rate (FDR) of 1%, identified a total of 3760 protein groups in the soluble
brain protein fraction (Figure 1C). Of these, only proteins that were identified in at least two out of
four biological replicates for each group (disease or control) at each time point were used for further
analyses. In this way, between 2414 and 2574 proteins were quantified depending on the time point.
Pearson’s correlation coefficients for quantified proteins between biological replicates were above
0.96 attesting to the high reproducibility of the data (Figure 1—figure supplement 2).
Principal component analysis of the datasets revealed that these proteins can be clustered
according to age (component 1, 40.9% of total variation) as well as disease state (component 2,
18.3% of total variation) (Figure 1D). Notably, increasing difference between control and AD brain
proteome could be observed with aging and disease progression (Figure 1D). The segregation by
age was mainly driven by extracellular matrix proteins (Hapln2, Tnc, Acan, Vcan, Hapln1) and
increased expression of microglia markers (S100b, Ctpd) (Figure 1E). Many of these proteins have
been previously reported as markers of brain aging (Sato and Endo, 2010; Ve´gh et al., 2014). The
samples segregated by principle component two varied primarily in the expression of AD-related
genes. As expected, APP and tau (MAPT) were clustered together with proteins upregulated in AD
(Figure 1E).
Relating proteome changes to biological processes in AD progression
To determine which biological processes were significantly affected with relation to disease progres-
sion, we subjected the dataset to Ingenuity Pathway Analysis (IPA) (QIAGEN Inc, https://www.qia-
genbioinformatics.com/products/ingenuity-pathway-analysis). We grouped the processes based on
the trend of their activation z-score at early (6 months, Figure 2A), intermediate (12 months,
Figure 2B) and late symptomatic time points (18 months, Figure 2C). Remarkably, cumulative upre-
gulation in expression of proteins involved in cell death and apoptotic processes could already be
detected at the first symptomatic time point (6 months) (Figure 2A). Signatures of mitochondria dys-
function were also among the very first signs of altered AD proteome (Figure 2A,B). Significant
changes in regulation of proteins associated with seizures were also observed at the transition point
between presymptomatic phase and 6 months which corresponds to the stage where changes in
long-term potentiation (LTP) in 3Tg-AD mice were previously described (Oddo et al., 2003b;
Palop et al., 2007). Neurodegeneration-related processes (amyloid load of hippocampus, demyelin-
ation of axons and degradation of mitochondria) were also noticeably exacerbated with AD progres-
sion (Figure 2B,C). Notably, disturbance of the cytoskeleton, which is a hallmark of many
neurodegenerative disorders including AD, became prominent only at the late stage of the disorder
(18 months) (Figure 2C) and correlated with the emergence of hyperphosphorylated tau in 3Tg-
AD mice (Figure 1—figure supplement 1).
To identify the primary drivers of the phenotypes observed at each stage, identification of top
upstream regulators was performed using IPA. This revealed that mutant tau, APP and PSEN1 were
principally responsible for the differences observed between wild-type and 3Tg-AD brains (Fig-
ure 2—figure supplement 1A). Interestingly, the proteins that are regulated by tau, APP and
PSEN1 in our dataset largely overlap (Figure 2—figure supplement 1B). Protein enrichment by bio-
logical function indicates that these downstream effectors contribute primarily to apoptosis, mito-
chondria dysfunction and oxidative stress (Figure 2—figure supplement 1C).
To identify potential markers indicative of disease onset and progression, we scanned the dataset
for proteins with the highest degree of fold-change at each AD stage. Therefore, proteins demon-
strating more than 50% change in expression level between disease and control that was statistically
significant (t-test, p<0.05) were shortlisted (Figure 2D–G). Among these, groups of proteins involved
in the same biological function could be identified. For instance, several proteins involved in mRNA
processing (Hnrnpm, Hnrnpl, Nono, Matrin3) were strongly upregulated at the later time points.
Remarkably, expression of these proteins increased gradually in coordinated manner throughout the
progression of the disorder (Figure 2H). A similar coordinated expression pattern was also observed
for the group of serine protease inhibitors (Serpina1c, Serpina3k, Mug1) which were significantly
downregulated by the latest time point examined (Figure 2I). This result is particularly interesting in
light of recent findings linking a reduction in protease inhibitors levels to aging and cognitive decline
Yagensky et al. eLife 2019;8:e47498. DOI: https://doi.org/10.7554/eLife.47498 4 of 33
Research article Neuroscience
Figure 2. Comparative proteome analysis of 3Tg-AD and control samples at different stages of AD. (A, B, C) Activation of biological processes at
different stages of the disease assessed by Ingenuity Pathway Analysis (IPA). Heat maps represent activation z-score change over the course of disease
progression and indicate pathways that are activated at 6M (A), 12M (B) and 18M (C). Data were obtained from four biological replicates per group for
each time point. Z-score is calculated based on experimental protein expression data (log2 AD/control ratio) and the theoretical information stored in
the IPA Knowledge Base. Positive value of z-score indicates an activation of biological pathway or function. Distribution of the quantified proteins at 2M
(D), 6M (E), 12M (F) and 18M (G) based on log2 ratio AD/Control and p-value (t-test) by time point. The pie charts represent the number of quantified
non-regulated proteins (grey), significantly different proteins between 3Tg-AD and control samples, t-test p-value 0.05 (pink) and significantly
regulated proteins with more than 50% expression change in comparison to the control (red). (H–I) Dynamics of protein expression over the course of
AD progression for a selection of the most regulated proteins based on their function. Proteins involved in mRNA processing and transport (H) that are
upregulated over time and serine protease inhibitors (I) that are downregulated. (J–M) Putative presymptomatic protein markers of the disease. (J) Top
Figure 2 continued on next page
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(Castellano et al., 2017). We have also identified several inflammation-related proteins (C1qc, Ilf2,
Igh-3) and components of myelin sheath (Mag, Mog) to be strongly up- or downregulated at the pre-
terminal stage of the disorder (18 months). This hints towards progressive inflammation and demye-
lination in the analyzed 3Tg-AD model which has been linked to AD (Wyss-Coray and Rogers,
2012; Zhan et al., 2014).
Presymptomatic protein markers of AD
We further narrowed our analyses to focus on proteins with the strongest fold changes at the pre-
symptomatic stage for two main reasons. First, these proteins could be useful as potential early
markers indicative of disease onset. Second, they might be responsible for causing the initial patho-
genic alterations. Thus, deciphering their function can help us better understand the initial cascade
of events driving the onset of AD. We identified strongly up- or downregulated proteins at the 2
month time point (Figure 2J) and corroborated the most prominent hits by immunoblotting against
protein samples obtained from the respective 2-month-old animals (Figure 2K). Many of these pre-
symptomatic markers maintained their expression levels across later time points in 3Tg-AD mice,
suggesting their relevance for the late stages of AD as well (Figure 2L,M). Noteworthy, half of the
identified putative early markers were previously associated with AD or other neurodegenerative dis-
orders (Table 1). For example, decreased levels of ApoA1 that we observe in our dataset have been
linked to the increased severity of AD in human patients (Merched et al., 2000; Saczynski et al.,
2007). Guanosine monophosphate reductase 1 (Gmpr) which was identified to be expressed at
increased levels in the brains of AD patients followed the same direction of change in our dataset
(Liu et al., 2018). Glyoxalase-1 (Glo1), another protein whose elevated expression was detected in
our study, was previously shown to be upregulated in other mouse models of neurodegeneration
(Chen et al., 2004). Furthermore, restoration of Glo1 activity has been proposed as a mechanism to
combat cognitive dysfunction in AD (More et al., 2013).
Among the newly identified putative presymptomatic markers of AD, heme-binding protein 1
(Hebp1) is a particularly interesting candidate. In our dataset, it was the most highly and consistently
upregulated protein at all time points. Hebp1 belongs to the SOUL protein family and was originally
identified as a tetrapyrol-binding protein capable of binding protoporphyrin IX and heme
(Jacob Blackmon et al., 2002; Dias et al., 2006; Taketani et al., 1998). Heme is essential for proper
mitochondria function and cell survival (Atamna, 2004). Impairments in heme metabolism are also
associated with AD (Atamna and Frey, 2004). Our data show that cell survival and mitochondria
function might be among the first pathways affected in AD (Figure 2A and B; Figure 2—figure sup-
plement 1C). To the best of our knowledge, no information on Hebp1 function in the brain is avail-
able to date. We thus further investigated the function of Hebp1 and its potential role in Alzheimer’s
disease.
Hebp1 is upregulated in rapidly-progressing cases of human AD
To verify the relevance of our findings in the mouse model for the disorder in humans, we examined
the expression of Hebp1 and Glo1, the two most upregulated early markers, in postmortem brain
samples obtained from AD patients and age-matched healthy controls (Figure 3; detailed patient
information is provide in Table 2). We could confirm an overall increase in expression of both pro-
teins in AD patients compared to controls that validated our findings obtained in the 3Tg-AD
Figure 2 continued
10 significantly up- and downregulated proteins in 3Tg-AD mice at presymptomatic time point (2M). (K) Immunoblot analysis of most regulated hits.
Soluble fractions of brain proteins were analyzed from four 2-month-old control and 3Tg-AD mice animals, respectively. Hebp1 and Glo1 levels were
consistently elevated in the transgenic animals as compared to wild type controls. Ca1 levels were reduced in transgenic animals. Presymptomatic
markers that remain up- (L) or downregulated (M) across the AD progression.
DOI: https://doi.org/10.7554/eLife.47498.005
The following source data and figure supplement are available for figure 2:
Source data 1. Full list of quantified proteins in the soluble brain fraction of 3Tg-AD and wild-type mice.
DOI: https://doi.org/10.7554/eLife.47498.007
Figure supplement 1. Analysis of upstream regulators.
DOI: https://doi.org/10.7554/eLife.47498.006
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model. Interestingly, a strong difference in expression of Hebp1 and Glo1 was primarily observed in
rapidly-progressing AD cases (death within 4 year period after diagnosis) (Figure 3B and C). These
cases of AD are characterized by distinct pathological features and clinical parameters and are asso-
ciated with a faster progression and more severe form of the disease (Chitravas et al., 2011;
Zafar et al., 2017a).
We have additionally examined the publicly available mRNA expression datasets to determine
the levels of Hebp1 in larger cohorts of AD patients (http://www.genenetwork.org/webqtl/main.py)
(Figure 3—figure supplement 1). The datasets from Harvard Brain Tissue Resource Center (GN326,
GN327, GN328) demonstrated significantly increased levels of HEBP1 mRNA in prefrontal and pri-
mary visual cortex in AD patients stressing a strong relevance of Hebp1 to AD in humans. Taken
together, these results support our findings that Hebp1 is indeed a novel protein dysregulated in
Alzheimer’s disease that is particularly associated with severe AD cases.
Hebp1 is a neuronal protein upregulated in the brain of 3Tg-AD
mouse
To better understand the function of Hebp1 and how it contributes to the disease, we first examined
its distribution in the brain. Immunoblot analyses of four brain areas in 12-month-old mice indicated
that Hebp1 was most abundant in the hippocampus, followed by the brain stem and cortical areas




AD/Ctrl Previous involvement in AD Reference
Upregulated presymptomatic markers
Hebp1 Heme binding protein 1 1.28 - -
Glo1 Glyoxalase 1 1.24 " in human brain, mouse model of FTD (Chen et al., 2004), (More et al.,
2013)
Blvrb Biliverdin Reductase B 0.74 " in plasma (Mueller et al., 2010)
Tsnax Translin Associated Factor X 0.72 - -
Gmpr Guanosine Monophosphate Reductase 0.70 " human brain, early stage (Liu et al., 2018)
Vim Vimentin 0.62 " in human brain (astrocytes) (Yamada et al., 1992)
Spag9 Sperm Associated Antigen 9 0.46 - -
Gpd1 Glycerol-3-Phosphate Dehydrogenase 1 0.43 Accumulation in NFT (Wang et al., 2005)
Dpysl4 Dihydropyrimidinase Like 4 0.40 - -
Tnik TRAF2 And NCK Interacting Kinase 0.22 Accumulation in insoluble fraction of amygdala in
cognitively impaired patients
(Gal et al., 2018)
Downregulated presymptomatic markers
Gng7 G Protein Subunit Gamma 7  0.60 - -
Atp2b4 ATPase Plasma Membrane Ca2+
Transporting 4
 0.60 # in human brain (Kong et al., 2015)
Enoph1 Enolase-Phosphatase 1  0.60 - -
Apoa1 Apolipoprotein A1  0.60 # in plasma (Saczynski et al., 2007),
(Merched et al., 2000)
Cpne5 Copine 5  0.62 - -
Lrba LPS Responsive Beige-Like Anchor
Protein
 0.63 - -
Mboat7 Membrane Bound O-Acyltransferase
Domain Containing 7
 0.63 - -
Hrsp12 Ribonuclease UK114  0.71 " in CVN-AD model (Hoos et al., 2013)
Kcnj10 Potassium Voltage-Gated Channel
Subfamily J Member 10
 0.86 # in mouse model of ALS (Kaiser et al., 2006)
Ca1 Carbonic anhydrase 1  1.23 - -
DOI: https://doi.org/10.7554/eLife.47498.008
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(Figure 4A). Hebp1 was not detectable in the cerebellum. Significantly, Hebp1 became dramatically
elevated in all four brain regions in age matched 3Tg-AD mice (Figure 4A). Immunohistochemical
analysis confirmed upregulated expression of Hebp1 in neocortex and hippocampus of 3Tg-AD
mice compared with wild-type controls (Figure 4B, Figure 4—figure supplement 1).
To identify which cell types express Hebp1 in the brain, we performed co-immunostaining of
Hebp1 with cell-lineage specific markers (Figure 4C, Figure 4—figure supplement 2). Hebp1 is
strongly expressed in Ctip2-immunoreactive neurons but is poorly associated with GFAP-stained
astrocytes or Iba-1-labeled microglia in the hippocampus.
Hebp1 interacts with mitochondrial contact site complex
While the role of Hebp1 in neurons has not been characterized, previous studies of Hebp1 and its
homologues have left some clues regarding its potential function. Hebp1 has been proposed to par-
ticipate in transport of heme from mitochondria to cytosol (Jacob Blackmon et al., 2002;
Taketani et al., 1998). Furthermore, heme-binding protein 2/SOUL, a homologue of Hebp1, is
involved in mediation of cell death by recruitment to mitochondria permeability transition pore
(Szigeti et al., 2006; Szigeti et al., 2010). Given the heme-binding properties of Hebp1 and evolu-
tionary similarity to Hebp2/SOUL, we hypothesized that it can perform one of these functions
(Fortunato et al., 2016).
Figure 3. Hebp1 and Glo1 exhibit increased expression in brains of patients with rapidly-progressing forms of AD.
(A) Immunoblot analysis of Hebp1 and Glo1 expression in slow-progressing (spAD) and rapidly-progressing (rpAD)
AD cases and age-matched controls. Samples from nine control, eight slow-progressing AD and eight rapidly-
progressing AD patients were used in this study. Detailed information on the patients is presented in Table 2.
Quantification of (B) Hebp1 and (C) Glo1 levels in human samples. Error bars in graphs represent mean ± SD.
Statistical significance in the datasets was assessed by one-way ANOVA followed by Bonferroni’s multiple
comparisons test for individual pairs of samples (a = 0.05): *p<0.025, **p<0.01, and ***p<0.0001.
DOI: https://doi.org/10.7554/eLife.47498.009
The following figure supplement is available for figure 3:
Figure supplement 1. HEBP1 expression in publicly available transcriptome databases of Alzheimer’s disease.
DOI: https://doi.org/10.7554/eLife.47498.010
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In this case, mitochondrial or perimitochondrial localization of Hebp1 would be expected. Previ-
ous studies aiming to define the mitochondrial proteome led to ambiguous results with regard to
mitochondrial localization of Hebp1 (Calvo et al., 2016; Hung et al., 2014; Hung et al., 2017). Sub-
cellular fractionation of the mouse brain indicated that Hebp1 is present in both synaptosomal (P2)
and crude mitochondrial (Mt) fractions where mitochondria are expected to be present (Figure 5A).
We further demonstrated that the protein can be mitochondrially-associated by detecting the pres-
ence of Hebp1 from mitochondria isolated from cultured hippocampal neurons (Figure 5B). Sup-
porting the biochemical data, we observed that a portion of EGFP-tagged Hebp1 expressed in rat
primary neurons appears to be closely juxtaposed to mitochondria (visualized using Mitotracker)
(Figure 5C and line scans in Figure 5E and F). In comparison to this, the signal from EGFP alone
exhibited no correlated association with Mitotracker (Figure 5C and D).
We further examined the role of Hebp1 in neurons by identification of its binding partners. To
this end, we performed immunoprecipitation of expressed EGFP-tagged Hebp1 in neurons using
GFP-trap and investigated the co-precipitated proteins by MS analysis. The volcano plot represents
the relative enrichment of detected proteins in either Hebp1-EGFP or EGFP (negative control) pull-
downs (Figure 6A). Interestingly, the core components of mitochondrial contact site complex
(MICOS), Mic60, Mic19 and Mic25, as well as proteins of outer mitochondria membrane associated
with MICOS complex, SAMM50 and Mtx2, were enriched in Hebp1 Co-IP samples. We further
Table 2. Information of patients included in this study.
Patient ID Gender Age Disease duration (years) Braak stages (AD)
Postmortem delays
[hours]
Cont. 1 Male 86 - II/A 06:45
Cont. 2 Male 61 - I/0 03:03
Cont. 3 Male 74 - II/A 11:00
Cont. 4 Male 86 - II/A 06:45
Cont. 5 Female 73 - I/0 04:03
Cont. 6 Male 69 - II/A 05:03
Cont. 7 Male 68 - I/0 05:03
Cont. 8 Female 64 - I/0 09:00
Cont. 9 Male 67 - I/0 05:03
spAD1 Female 72 >4 V/C 09:30
spAD2 Female 75 >4 V/C 04:15
spAD3 Male 78 >4 V/C 09:30
spAD4 Male 83 <4 V/C 08:20
spAD5 Female 56 >4 V/C 07:00
spAD6 Male 83 >4 III/0 07:25
spAD7 Female 90 >4 IV/A 09:55
spAD8 Female 93 >4 V/C 03:00
rpAD1 Male 78 <4 V/C 03:30
rpAD2 Female 79 <4 V 05:30
rpAD3 Female 81 <4 III/B 06:00
rpAD4 Male 83 <4 VI/C 05:30
rpAD5 Male 83 <4 V/C 08:20
rpAD6 Male 70 <4 VI/C 11:30
rpAD7 Male 76 <4 VI/C 06:30
rpAD8 Female 77 <4 IV/A 12:00
DOI: https://doi.org/10.7554/eLife.47498.011
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confirmed the interaction between Hebp1 with Mic60 by probing the immunoprecipitated com-
plexes with their respective antibodies via immunoblotting (Figure 6B). Taken together these data
indicate that Hebp1 locates in close proximity to the mitochondrial outer membrane where it inter-
acts with MICOS complex potentially through association with outer mitochondria membrane pro-
teins such as SAMM50 or Mtx2. In line with our observations, a very similar pattern of subcellular
localization was observed in cells that were transfected with full-length Hebp2/SOUL (Szigeti et al.,
2006), further hinting towards potential role of Hebp1 in the regulation of cell death.
Hebp1 facilitates heme-mediated cytotoxicity
Heme metabolism, cell death response and AD are tightly interconnected. Dysregulation of proteins
linked to heme metabolism has been reported in AD (Hani Atamna & Frey, 2004; Schipper et al.,
1995). Moreover, Ab can form a complex with heme which possesses strong peroxidase and super-
oxide activities that can contribute to oxidative stress and cytotoxicity during AD (Atamna and
Boyle, 2006; Chiziane et al., 2018; Ghosh et al., 2015). Accumulation of Ab around brain vascula-
ture results in cerebral amyloid angiopathy (CAA), microvessel destruction and leakage of free heme
into brain tissue (Chiziane et al., 2018). Due to its strong hydrophobicity, heme is almost exclusively
bound to carrier proteins within cells. High concentrations of free heme are toxic to multiple cell
types (Gemelli et al., 2014; Owen et al., 2016). We wondered whether Hebp1 could protect neu-
rons by acting as an intracellular heme buffer to maintain the latter at low levels. To test this hypoth-
esis, we successfully eliminated expression of Hebp1 in rat hippocampal neurons using CRISPR/Cas9
using three different gRNA sequences (Figure 7A, KO1-3). We then exposed both control and
Figure 4. Analysis of Hebp1 expression in the brain of 3Tg-AD mice. (A) Expression of Hebp1 in 12-month-old control and 3Tg-AD mice by brain
region. (B) Hebp1 immunostaining of the fronto-temporal cortex depicting primary motor and somatosensory areas and hippocampus (coronal
sections). CA1 region is marked with the white dashed line. (C) Co-staining of Hebp1 with markers of CA1 and dentate gyrus neurons (Ctip2), astrocytes
(GFAP) and microglia (IBA-1) in the hippocampus of 3Tg-AD mice. Hepb1 is expressed predominantly in Ctip2-positive cells of hippocampus
(neurons). All images were acquired from 12-month-old control or 3Tg-AD mice. Scale bar is 100 mm. All data shown are representative of results
obtained from three independent experiments.
DOI: https://doi.org/10.7554/eLife.47498.012
The following figure supplements are available for figure 4:
Figure supplement 1. Expression of Hebp1 in brains of control and 3Tg-AD mice.
DOI: https://doi.org/10.7554/eLife.47498.013
Figure supplement 2. Expression of Hebp1 is localized to neurons.
DOI: https://doi.org/10.7554/eLife.47498.014
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Figure 5. Hebp1 demonstrates perimitochondrial localization in neurons. (A) Brain fractionation was performed as described before (Huttner et al.,
1983). Hebp1 was identified in crude mitochondria fraction (Mt). Fraction annotation: H – homogenate, S1 – supernatant 1, P1 – pellet 1, S2 –
supernatant 2 (fraction of soluble proteins), P2 – pellet 2 (synaptosomes), Mt – mitochondria, LP1 – lysate pellet 1 (plasma membrane fraction of
synaptosomes), LS1 – lysate supernatant 1 (soluble fraction of synaptosomes). 20 mg of each fraction were loaded on the gel, except for LS1 (6 mg). (B)
Figure 5 continued on next page
Yagensky et al. eLife 2019;8:e47498. DOI: https://doi.org/10.7554/eLife.47498 11 of 33
Research article Neuroscience
Hebp1-deficient neurons to exogenous hemin and measured the extent of cytotoxicity by determin-
ing the activity of the dead cell protease.
Consistent with the cytotoxic effects of high heme levels, treatment of wildtype (WT) and control
neurons (LUC) with hemin resulted in 2.69 (±0.15) and 2.86 (±0.23) fold increase in cell death for WT
and LUC respectively as compared to exposure to vehicle only (Figure 7B). Strikingly, Hebp1-defi-
cient neurons exhibited no significant cell death. This effect was consistently observed in both the
gRNA sequences used (Figure 7B, KO1 and KO2). Thus, contrary to our expectations, Hebp1 does
not protect neurons from excessive heme. Rather, the protein apparently mediates its toxic effect.
To confirm the specificity of heme as the inducer of Hebp1-dependent cell death, we also exposed
the neurons to tert-butyl-hydroperoxide (stable analog of hydrogen peroxide) or staurosporine,
both of which are known inducers of apoptotic cell death (Belmokhtar et al., 2001; Zhao et al.,
2017). As expected, all 3 groups of neurons exhibited increased levels of cellular toxicity, confirming
that loss of Hebp1 is protective towards hemin-induced cytotoxicity (Figure 7C and D). We also
evaluated if over-expression of Hebp1 could affect cytotoxicity. Increased hemin-induced cytotoxic-
ity was observed for Hebp1-EGFP expressing neurons as compared to EGFP-expressing neurons
(Figure 7—figure supplement 1). However, this increase did not reach statistical significance.
Figure 5 continued
Mitochondria were isolated from cultured hippocampal neurons as described previously (Wieckowski et al., 2009). Hebp1 was only detected in
isolated mitochondria together with Cox4 while markers for endo-lysosomal, synaptic and plasma membrane compartments (Lamp1, tubulin, Stx1,
Rab5, Rab6 and VAMP2) were exclusively present in the supernatant. (C) Localization analysis of mitochondria (mitotracker), Hebp1-EGFP and EGFP
alone in cultured rat hippocampal neurons (DIV14). Hebp1 puncta is associated with mitochondria. Representative line scans (golden lines in the inserts;
location of the numbers correspond to the starting point of each analysis) were traced for EGFP control (D) and Hebp1-EGFP (E–F). Line scan analyses
indicate that at least some of the Hebp1-EGFP puncta appear to be contacting mitochondria (E–F). Scale bar is 10 mm. All data shown are
representative of results obtained from three independent experiments.
DOI: https://doi.org/10.7554/eLife.47498.015
Figure 6. Hebp1 interactome reveals its association with mitochondrial contact site complex (MICOS). (A) Hebp1 interactome obtained by mass
spectrometry analysis of proteins co-immunoprecipitated from primary cortical neurons with Hebp1-EGFP or EGFP (negative control). Enrichment of
mitochondria contacts site complex (MICOS) proteins (red) or MICOS-associated proteins (orange). Dashed line represents a cut-off for significantly
different proteins between Hebp1-EGFP and control pulldown with at least 4-fold change. (B) Validation of Hebp1-Mic60 interaction by
immunoblotting. All data shown are representative of results obtained from three independent experiments.
DOI: https://doi.org/10.7554/eLife.47498.016
The following source data is available for figure 6:
Source data 1. Hebp1 interactome.
DOI: https://doi.org/10.7554/eLife.47498.017
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Figure 7. Hebp1 mediates neurotoxicity upon heme overload. (A) Knockout of Hebp1 in neurons by CRISPR/Cas9. (B) Measurement of cytotoxicity
using the MultiTox-Glo reagent (Promega) was performed 24 hr after stimulation with 10 mM hemin or vehicle. Hebp1-deficient neurons are resistant to
heme-mediated cytotoxicity. Wildtype, control and Hebp1-deficient neurons demonstrate similar elevated cytotoxicity in response to 3 hr treatment
with 25 mM tert-butyl hydroperoxide (C) and 1 mM staurosporine (D). (E) Hemin treatment induces significantly higher reduction of mitochondrial
potential in Hebp1-deficient neurons in comparison to wildtype and control neurons. Mitochondrial potential was measured using the Mitochondrial
Membrane Potential Assay kit (Cell Signaling). All bar charts represent mean ± SEM. Statistical significance in the datasets was assessed by one-way
ANOVA followed by Student’s t-test comparison for individual pairs of samples: ***p<0.005 and ****p<0.001. All data shown are representative of
results obtained from three independent experiments.
DOI: https://doi.org/10.7554/eLife.47498.018
The following figure supplement is available for figure 7:
Figure supplement 1. Cytotoxicity is influenced by hemin concentrations rather than cellular levels of Hebp1.
DOI: https://doi.org/10.7554/eLife.47498.019
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Instead, statistically significant increases in cytotoxicity were observed when hemin concentrations
were raised from 5 to 10 mM within the EGFP or EGFP-Hebp1 expressing group. These results indi-
cate that endogenous levels of Hebp1 are sufficient to trigger neuronal cell death that is, in turn,
influenced by heme concentrations.
As described in the preceding paragraphs, Hebp1 is localized to mitochondria via its interaction
with the MICOS complex. Of note, Mic60 plays important roles in critical aspects of mitochondrial
function and integrity and has been linked to mitochondrial-associated apoptosis (Van Laar et al.,
2018). In particular, reduction of Mic60 in cells has been associated with release of Cytochrome C
(CytC) and increased sensitivity to apoptosis triggers (Yang et al., 2012). Release of CytC, often
associated with loss of mitochondrial potential, is followed by Apaf1 activation and the ensuing con-
version of procaspase 9 into caspase 9 and procaspase 3 into caspase 3, thereby committing the
cells into apoptosis (Franklin and Robertson, 2007; Zou et al., 1999). The interaction of Hebp1
with Mic60 suggests that Hebp1-dependent apoptosis in response to excess heme might be initi-
ated at the mitochondria. Indeed, exposure of neurons to hemin decreases mitochondrial membrane
potential (MMP) in wildtype, control as well as Hebp1-deficient neurons (Figure 7E). However, a
steeper decrease in MMP was observed in Hebp1-deficient neurons (58.7 ± 2.83% and 60.9 ± 1.77%
in KO1 and KO2 neurons) as compared to the other two groups (15.1 ± 2.77% and 14.1 ± 0.22% in
wildtype and control neurons, respectively) strongly suggesting that effects on mitochondrial mem-
brane potential alone cannot be the sole explanation for Hebp1’s role in causing neuronal
apoptosis.
Indeed, using mitochondria isolated from these neurons, we observe that CytC was released from
these organelles in all neurons (wildtype, control and Hebp1-deficient) treated with hemin
(Figure 8A and B), confirming that this step of mitochondria-associated apoptosis is not affected by
loss of Hebp1 function. Strikingly, we observe that while procaspase 9 was cleaved in wildtype and
control neurons upon hemin-treatment, the protein was not activated in Hebp1-deficient neurons
(Figure 8C). In agreement with this, hemin exposure caused a dramatic increase in the population of
caspase 3+/7+ cells in wildtype (58.5 ± 2.89%) and control neurons (62.4 ± 1.88%) but not in Hebp1-
deficient neurons (8.69 ± 1.55% and 9.86 ± 2.09% in KO1 and KO2, respectively) (Figure 8D and E).
Noteworthy, Hebp1, found almost exclusively in the mitochondrial fraction in untreated wildtype
and control neurons, was released from the mitochondria of these neurons upon exposure to hemin
(Figure 8B). Collectively, these results indicate that release of mitochondrial Hebp1 in the presence
of excessive heme is a critical trigger linking mitochondrial damage to neuronal apoptosis via activa-
tion of the procaspase 9 pathway. Interestingly, Mic60 was also released from mitochondria, but
only in Hebp1-deficient cells, while Cox4 remained in the mitochondrial pellet for all groups of neu-
rons. The significance of this remains unclear.
We also examined if absence of Hebp1 could also protect neurons from exposure to Ab42. As
expected, cytotoxicity was observed in both wildtype (40.2 ± 1.23%) and control neurons (42.8 ±
1.15%) treated with Ab42 (Figure 9). Concurrent exposure of these neurons to Ab42 and hemin
caused an additional 2-fold increase in cytotoxicity (87.9 ± 1.04% for wildtype and 89.1 ± 0.63% for
control neurons), an additive effect presumably caused by formation of an Ab-heme complex that
can contribute to oxidative stress and cytotoxicity during AD (Atamna and Boyle, 2006;
Chiziane et al., 2018; Ghosh et al., 2015). In contrast to this, very low levels of cytotoxicity were
detected when Hebp1-KO neurons were exposed to Ab42 alone (7.51 ± 0.70% and 7.29 ± 0.96% in
KO1 and KO2, respectively), similar to hemin treatment (9.65 ± 0.77% and 9.42 ± 0.87% in KO1 and
KO2, respectively). Even more significantly, cytotoxicity levels remained low even after concurrent
treatment with Ab42 and hemin (22.9 ± 0.84% and 23.9 ± 0.84% in KO1 and KO2, respectively).
Thus, Hebp1 participates in converging pathways triggered by Ab42 and heme that cause cytotoxic-
ity via apoptotic cell death in neurons.
Discussion
In this study, we identified several potential presymptomatic brain markers of AD by examining
changes in brain proteome between wild-type and 3Tg-AD mice. Of these, Hebp1 is consistently
elevated in the brains of 3Tg-AD mice from early stage of the disease and is also significantly
increased in postmortem brains of patients affected by rapidly-progressing forms of AD. Hebp1
appears to be mainly expressed in neurons where it is associated with mitochondria via the MICOS
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Figure 8. Neuronal cell death occurs by triggering mitochondrial-dependent apoptotic pathway in Hebp1-expressing neurons. Western blot analyses
of (A and B) CytC and Mic60 leakages and (C) caspase 9 activation in Hebp1-deficient, wildtype and control neurons. Wildtype and control neurons
exhibited high levels of activated caspase 9 concomitant with mitochondrial release of CytC and Mic60 into the cytosol (S). Hebp1 release was also
coupled with leakage of CytC and Mic60 in these cells. In contrast, Hebp1-deficient neurons displayed no apparent activation of caspase 9 despite
Figure 8 continued on next page
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complex. Strikingly, knockdown of Hebp1 expression in neurons protects them from both heme-
and Ab42-induced apoptosis, suggesting that Hebp1 plays a role in sensitizing neurons to cytotoxic-
ity over the course of AD progression.
Figure 8 continued
leakages of CytC and Mic60 from neuronal mitochondria (Mt). (D) Wildtype, control and Hebp1-deficient neurons were treated with 10 mM hemin for 24
hr. Apoptotic cells were visualized by fluorescence staining corresponding to caspase 3/7 activation (see Materials and methods). Hebp1-deficient
neurons demonstrated resistance to apoptosis upon heme overload, whereas wildtype and control neurons exhibited high levels of caspase 3/7 activity.
(E) Quantification of the data represented by the images shown in (D). All bar charts represent mean ± SEM. Statistical significance in the datasets was
assessed by one-way ANOVA followed by Student’s t-test comparison for individual pairs of samples: ****p<0.001. All data shown are representative of
results obtained from three independent experiments.
DOI: https://doi.org/10.7554/eLife.47498.020
Figure 9. Knockout of Hebp1 in neurons is neuroprotective against hemin and/or Ab42-induced neuronal cell death. (A) Wildtype, control and Hebp1-
deficient neurons were treated with 10 mM hemin or 10 mM Ab42 oligomers or both simultaneously (10 mM each). Apoptotic cells were observed for
caspase 3/7 activation via fluorescence staining (see Materials and methods). Hebp1-deficient neurons showcased resistance to apoptosis upon heme
and/or Ab42 overload, with wildtype and control neurons exhibiting opposing effects of highly elevated caspase 3/7 activity. (B) Quantification of the
data represented by the images shown in (A). All bar charts represent mean ± SEM. Statistical significance in the datasets was assessed by two-way
ANOVA followed with Bonferroni corrections for individual pairs of samples: ****p<0.001. All data shown are representative of results obtained from
three independent experiments.
DOI: https://doi.org/10.7554/eLife.47498.021
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Our study indicated that proteins related to cell death, mitochondria function and seizures are
among the first affected in AD. Alterations of cytoskeleton-related proteins became apparent only
at the late stage of the disorder which coincides with the timeline of tau aggregation. Several pro-
teins in our dataset exhibited gradual increases in expression that correlated with disease progres-
sion in 3Tg-AD mice. These included proteins that are involved in mRNA processing such as
Matrin-3 and Nono that form a complex involved in DNA damage response and recognition and
retention of incorrectly processed mRNA in nucleus (Salton et al., 2010; Zhang and Carmichael,
2001). Similar expression patterns were detected for Hnrnpm and Hnrnpl, which regulate alternative
splicing (Fei et al., 2017; Passacantilli et al., 2017). Bai and colleagues have previously found U1
snRNP components to be enriched in insoluble brain proteome of AD patients and demonstrated
impaired splicing of AD-related transcripts (Bai et al., 2013). While the role of mRNA processing
and alternative splicing in AD has not been studied extensively, our observations point towards dys-
regulation of this process in 3Tg-AD mice. We also observed that several inhibitors of serine pro-
teases (serpins) appear to progressively decrease in expression during the monitoring period.
Interestingly, a recent study of the hippocampal proteome in the 5  FAD mouse model of AD also
identified downregulation of serpins (Gurel et al., 2018). Protease inhibitors hold a potential as ther-
apeutic targets since their levels in the brain can be restored through injection of recombinant pro-
tein. This approach was recently tested with metalloprotease inhibitor TIMP2 which was injected
intraperitoneally to reach the brain and improve the cognitive function of aged mice
(Castellano et al., 2017).
The present study uncovered two proteins, Hebp1 and Glo1, that were highly elevated already at
the presymptomatic stage in 3Tg-AD mice, suggesting that they could be of potential relevance as
early AD markers. Both proteins were also expressed at significantly higher levels - particularly in
rapidly progressing cases of AD - indicating that they could be of use to identify this group of
patients. While Glo1 has been previously linked to neurodegeneration (Chen et al., 2004;
More et al., 2013), our study is the first to report the involvement of Hebp1 in AD.
According to our data, Hebp1 is predominantly expressed in neurons in both wild-type and
3Tg-AD mice where it is associated with mitochondria via interaction with the MICOS complex.
Interestingly, Mic60, a component of the MICOS complex that binds Hebp1, is also an important
player in cell death. Loss of Mic60 increases the rate of apoptosis due to dissipation of cristae junc-
tions and intensifies leakage of CytC from mitochondria to cytosol (Yang et al., 2012). Moreover,
SOUL, a homolog of Hebp1, promotes cell death presumably through permeabilization of mitochon-
dria membranes (Szigeti et al., 2006; Szigeti et al., 2010). Together, these findings suggest that
Hebp1 itself could also be involved in causing cellular toxicity.
What implications might heme-mediated cell death have for AD? Loss of neurons is a key event
leading to cognitive decline in AD and is mainly attributed to intensified apoptosis (Cotman and Su,
1996). Overexpression of proteins counteracting apoptotic response has been previously shown to
decrease pathology in 3Tg-AD mice (Rohn et al., 2008). Degradation of heme by heme oxygen-
ase-1 was demonstrated to reduce cytotoxicity caused by Ab1–42 peptide (Hettiarachchi et al.,
2014). Heme synthesis is impaired in AD and accumulation of immature heme species can be a
potential source of heme overload (Hani Atamna & Frey, 2004). Excessive heme can also come from
circulating blood. Cerebral amyloid angiopathy contributes significantly to AD both in human and
the 3Tg-AD model starting from the early stage of the disorder (Ghiso et al., 2010; Li and Pratico`,
2015). Moreover, pathophysiological changes in brain vasculature have also been reported in 3Tg-
AD mice (Grammas et al., 2014; Lin et al., 2014). Thus, CAA may lead to disruption of brain vascu-
lature and release of heme outside the vessels (Chiziane et al., 2018; Natte´ et al., 2001) and is also
associated with apoptosis (Fossati et al., 2010; Mattson, 2000). Collectively, these data highlight a
possible link between impairments of heme metabolism, neuronal loss and increased expression of
Hebp1 early in AD.
In agreement with this, we observe that Hebp1 is intimately involved in heme-induced neuronal
death. Indeed, while neurons expressing Hebp1 showed dramatically elevated levels of cell death,
Hebp1-deficient neurons were resistant to hemin-induced apoptosis. Likewise, neuronal cell death
via apoptosis triggered upon exposure to Ab42 was also significantly attenuated in Hebp1-deficient
neurons. Remarkably, Hebp1 sits at a critical, albeit currently unknown, position between upstream
activating events (mitochondrial membrane potential changes and CytC leakage) and the initiation of
the caspase cascade (Galluzzi et al., 2018). In Hebp1-deficient neurons, loss of Hebp1 and the
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consequent lack of release of the protein into the cytosol halted the activation of caspases 9 and 3/7
in spite of the occurrence of upstream activating events, suggesting that it could play a role in regu-
lating apoptosome formation which is vital in cleaving procaspase 9 to its functional form
(Saleh et al., 1999; Zou et al., 1999). The significance accompanying the observed concurrent
release of Mic60 in Hebp1-deficient neurons observed in response to hemin-treatment remains
unclear despite reduced levels of Mic60 being linked to CytC release (Yang et al., 2012). This would
be an important subject for further studies.
Hebp1 might also play further roles in AD pathology in addition to its newly uncovered functions
in this study. Two previous publications demonstrated that N-terminal cleavage of Hebp1 by cathep-
sin D results in generation of 21 amino acid long peptide called F2L that is capable of binding
FPRL1/FPR2 receptor on the surface of mouse neutrophils and promote their migration
(Devosse et al., 2011; Gao et al., 2007). In the mouse brain, FPR2 is expressed predominantly by
activated microglia (Cui et al., 2002). Moreover, FPRL1-positive microglia was shown to be recruited
to Ab plaques in AD patients (Le et al., 2001). In our dataset, expression of the Hebp1 protease
cathepsin D also strongly correlates with aging which indicates the possibility of the progressive F2L
accumulation in 3Tg-AD mice with age. Increased expression of cathepsin D in hippocampus of AD
patients was also reported previously (Hondius et al., 2016). Thus, it is possible that cleavage of
Hebp1 by cathepsin D in neurons may additionally generate the soluble F2L peptide to recruit acti-
vated microglia and modulate inflammatory response during AD.
Overall, our results provide a quantitative proteome map of AD progression in the 3Tg-AD
transgenic mouse model and identify several novel protein candidates that could serve as putative
presymptomatic markers of the disease. These data can serve as a starting point to allow for a more
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Mice
All animal procedures used in this study here fully comply with the guidelines as stipulated in the
section 4 of the Animal Welfare Law of the Federal Republic of Germany (section 4 of TierSchG, Tier-
schutzgesetz der Bundesrepublik Deutschland). 3Tg-AD mice (B6.129.Thy tr.tg-/-), generated on a
mixed 129/sv-C57bl6 genetic background (Oddo et al., 2003b), and control B6;129 (129/sv C57bl6
WT) mice were used for the experiments. For preparation of primary neurons, Wistar rats originated
from the local animal facility were used. All animals were maintained under 12L/12D cycle with food
and water ad libitum.
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Sample collection for mass spectrometry
Whole brains of male mice (both control and 3Tg-AD) were collected at 2, 6, 12 and 18 months of
age in four biological replicates. Half of the brain was immersion-fixed with 4% phosphate-buffered
paraformaldehyde and used for the immunohistochemical analysis. The other half was homogenized
by a glass-Teflon homogenizer (RW20-DZM, IKA) in 3 ml ice-cold homogenization buffer (containing
protease/phosphatase inhibitors, Pierce, Rockford, IL, USA, 88669) at 900 rpm for nine strokes.
Thereafter, the homogenate was centrifuged for 2 min at 3000  g, 4˚C in S100AT4 rotor (SORVALL)
to remove cell debris. Next, the supernatant was transferred to a new tube and additionally centri-
fuged for 12 min at 14500  g in S100AT4 rotor at 4˚C to obtain the soluble fraction of brain pro-
teins (supernatant).
Mass spectrometry sample preparation and measurement
The protein concentration of the samples was measured by Pierce 660 nm Protein Assay according
to the manufacturer’s protocol. 40 mg of protein were used for proteomic analysis. Proteins were
precipitated with four volumes of ice-cold acetone overnight at  20˚C. The protein pellet was resus-
pended in 1% RapiGest (Waters, 186002123) and incubated in thermoshaker at 60˚C for 15 min at
1050 rpm. The disulfide bonds were reduced by 10 mM dithiothreitol (Thermo Fisher Scientific,
Rockford, IL, USA, 20290) (60˚C for 45 min at 1050 rpm) and alkylated by 25 mM chloroacetamide
(Sigma, Steinheim, Germany, 22790) (37˚C for 30 min at 750 rpm). Proteins were then digested by
trypsin (Promega, Madison, WI, USA, V5113, 1:20, trypsin to protein ratio) in 50 mM ammonium
bicarbonate, pH 8, for 16 hr. Digestion was stopped by addition of 1% formic acid (37˚C for 1 hr
with shaking at 750 rpm) and the peptide solution was cleared by centrifugation (for 30 min at
21800  g at 4˚C). Obtained peptides were desalted using the C18 extraction disk (Sigma, 66883 U)
and dried in vacuum concentrator for MS analysis.
Fusion mass spectrometer (Thermo Fisher Scientific) coupled to Ultimate 3000 HPLC system (Agi-
lent Technologies, Santa Clara, CA, USA) was used for proteomic analysis. Peptides were loaded
onto a trap column packed in-house (100 mm ID 30 mm self-packed with Reprosil-Pur 120 C18-AQ
1.9 mm, Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) and separated at a flow rate of 300 nl/
min on an analytical column (75 mm ID 300 mm self-packed with Reprosil-Pur 120 C18-AQ, 1.9 mm,
Dr. Maisch HPLC GmbH). Peptides were eluted from the column with 5–76% linear gradient of
increasing buffer B (80% acetonitrile, 0.08% formic acid in water) and decreasing buffer A (0.1% FA
in water) with an overall run-time of 90 min. Separated peptides were ionized by electrospray ioniza-
tion source in a positive ion mode. Full-scan MS spectra were acquired in the range of 350–1550 m/z
at a resolution of 60,000 units. The top speed method was selected for fragmentation in the collision
cell with Higher-energy Collisional Dissociation with the normalized collision energy of 30% and iso-
lation window of 1.2 m/z.
Data processing and bioinformatics analysis
Acquired MS spectra were processed using the MaxQuant software package version 1.5.0.25
(Cox and Mann, 2008). Spectra were searched using the Andromeda search engine (Cox et al.,
2011) against the proteome database of Mus musculus (Uniprot complete proteome updated at
2014-05-13, with 24,504 entries). MaxQuant search was configured as follows: the mass tolerance
was set to 20 and 4.5 ppm for the first and the main peptide search, respectively; the multiplicity
was set to one; Trypsin/P was fixed as protease and maximum of 2 missed cleavages were allowed;
carbamidomethylation of cysteine was set as fixed modification and methionine oxidation as well as
N-terminal acetylation were specified as variable modifications; a false discovery rate of 1% was
applied; the re-quantification and match between runs options (Match time window 0.7 min, Align-
ment time window 20 min) were enabled.
The Protein Groups output file from the MaxQuant was processed by ‘Perseus’, version 1.5.5.3
for downstream data analysis (Cox and Mann, 2008). For each time point, proteins identified in at
least two out of four biological replicates in both control and disease group were selected for further
analysis. Reverse hits were removed. For Principal Component Analysis (PCA), the LFQ intensities
(Label-Free Quantification) were log2 transformed and averaged by group. PCA was performed in
‘Perseus’ with number of clusters set to five and Benjamini-Hochberg FDR cut-off of 0.05. For the
downstream proteomics analysis, the LFQ intensities of proteins reported by MaxQuant were log10
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transformed. The AD/Control intensity ratio for each protein was calculated and log2 transformed.
Proteins with AD/Control ratios showing a statistically significant (p-value<0.05; two-sample t-test)
fold-change of more than 1.5 or less than 0.667 were selected for further analyses (Figure 2D–G).
Time course changes in biological pathways and their top upstream regulators were identified by
Ingenuity Pathway Analysis (IPA, QIAGEN Inc, https://www.qiagenbioinformatics.com/products/
ingenuity-pathway-analysis) (Figure 2A–C, Figure 2—figure supplement 1). The log2 AD/Control
intensity ratios of all quantified proteins were used for the analysis with IPA. Positive z-score indi-
cates an overall upregulation (activation) of the process, while a negative score stands for its inhibi-
tion. The z-score was computed based on the measured protein expression values (log2 ratio AD/
control) and the information on the relationship between the proteins and biological processes they
are involved in stored in Ingenuity Knowledge Database.
Analysis of human mRNA expression datasets
Information on HEBP1 mRNA expression levels in AD patients was extracted from the transcriptome
dataset from the Harvard Brain Tissue Resource Center (HBTRC) that is publicly available on the
GeneNetwork website (www.genenetwork.org). Used datasets were human primary visual cortex
(GN Accession: GN327), human prefrontal cortex (GN Accession: GN328) and cerebellum (GN
Accession: GN326). These datasets were generated on a custom-made Agilent 44K microarray of
39,280 DNA probes uniquely targeting 37,585 known and predicted genes. The study includes 803
participants of which 388 Alzheimer’s disease cases, 220 Huntington’s disease cases and 195 con-
trols matched for gender, age and postmortem interval.
Postmortem human brain samples
All experimental protocols were approved and the study conformed to the Code of Ethics of the
World Medical Association. All study participants or their legal next of kin gave informed consent
and the study was approved by the local ethics committee in Go¨ttingen (No. 24/8/12). All samples
were anonymized with regard to their personal data. The brain samples were collected and provided
by the Prion Disease Surveillance Units of Germany including spAD, rpAD and non-demented con-
trol cohorts as described previously (Grau-Rivera et al., 2015; Zafar et al., 2017a). Briefly, patient
clinical records were retrospectively assessed and classified by two neurologists. Neuropathological
assessments were performed by immunohistochemical staining of tissue sections obtained from
patients using a selection of antibodies including those directed against b-amyloid and phosphory-
lated tau. Information on ages, genders, disease duration, disease stage (Braak classification;
Braak and Braak, 1991) and postmortem interval are summarized in Table 2. Brain tissue samples
were processed as demonstrated previously (Grau-Rivera et al., 2015; Zafar et al., 2017b).
Primary neurons and cell culture
Primary cortical or hippocampal neurons were prepared from postnatal day 0 Wistar rats. Dissected
cortices and hippocampi were digested for 30 min with papain enzymatic solution (Worthington Bio-
chemical Corporation, Lakewood, NJ, USA LS003126) in the presence of 1 mg/mL DNaseI (Sigma,
D5025). Digestion was stopped by addition of 0.25% BSA (AppliChem, Darmstadt, Germany,
A1391) in serum medium (Eagle’s MEM (Sigma M2414), 5% FBS (Pan Biotech, Aidenbach, Germany),
2 mM L-alanyl-L-glutamine (Millipore, Berlin, Germany, K0302), 1  MEM Vitamine (Sigma K0373),
Mito+Serum extender (Corning Costar, Kennebunk, ME, USA, 355006) supplemented with 3.8 g/L
D-glucose). Digested tissues were triturated using a fire-polished Pasteur pipette until no visible tis-
sue debris could be observed. The cell suspension was passed through a 40 mM cell strainer (Corning
Costar, 352340) and subsequently centrifuged for 5 min at 500 rpm followed by resuspension of cell
pellets in serum medium. Next, cortical neurons were plated in plating medium (DMEM/F12 (Sigma,
D6421), 1  B-27 (Invitrogen, Rockford, IL, USA, 17504044), 2 mM L-Alanyl-L-Glutamine) directly on
poly-D-lysine (PDL) coated 10 cm culture plates (Greiner, Frickenhausen, Germany, 664160) for Co-
IP analysis (one cortex per plate). Hippocampal neurons were plated on PDL-coated coverslips in
plating medium at a density of 20,000 cells/cm2 for imaging. Medium was changed completely to
fresh plating medium supplemented with 1  FUDR (Sigma, F0503) the next day.
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Immunoblotting
Protein samples were mixed with 4  NuPAGE LDS Sample Buffer (Thermo Fisher Scientific,
NP0008) and boiled at 95˚C for 5 min. 15 mg of protein sample were typically loaded on the gel.
Mouse brain samples and Co-IP samples were separated on 12% SDS-PAGE gels. Proteins were
transferred to nitrocellulose membrane using the Mini Trans-Blot Cell system (Bio-Rad, Hercules,
CA, USA) for 1 hr at constant voltage of 100 V. Human samples were run on 4–20% Criterion TGX
gels (Bio-Rad, 5671095) and transferred using Trans-Blot Turbo Transfer System (Bio-Rad). Mem-
branes were blocked in 5% non-fat dry milk in TBST (150 mM Tris-HCl, pH 7.4, 1.5 M NaCl, 0.5%
Tween20) for 1 hr at room temperature, incubated with primary antibodies in blocking solution over-
night, washed with TBST (five times, 5 min each), incubated with secondary antibodies for 1 hr at
room temperature and washed again with TBST (five times, 5 min each). Protein bands were visual-
ized using fluorescence or enhanced chemiluminescence with images developed using Odyssey CLx
Infrared Imaging System (Licor, Bad-Humburg, Germany) or Fujifilm LAS-100 device, respectively.
The following primary antibodies were used for immunoblotting: rabbit Hebp1 (1:1000, Invitro-
gen, PA5-30609), mouse Glo1 (1:1000, GeneTex, Irvine, CA, GTX628890), rabbit CA1 (1:250, Novus
Biologicals, Abingdon, UK, NBP1-88191), mouse a-tubulin (1:5000, Synaptic Systems, Go¨ttingen,
Germany, 302 211), rabbit b-actin (1:5000, Synaptic Systems, 251 003), rabbit GFP (1:5000, Synaptic
Systems, 132 002), mouse Rab5 (1:1000, Synaptic Systems, 108 111), rabbit Rab6 (1:1000, Synaptic
Systems, 273 003), rabbit Lamp1 (1:500, Abcam, ab24170), mouse Mic60 (1:1000, Abcam,
ab110329), rabbit Cox4 (1:1000, Synaptic Systems, 298 002), rabbit CytC (1:1000, Cell Signaling,
Beverly, MA, USA, 11940S), rabbit caspase 9 (1:1000, Abcam, Cambridge, UK, ab185719), mouse
Sodium Potassium ATPase, subunit a1 (1:1000, Abcam, Cambridge, UK, ab7671), mouse syntaxin 1
(1:1000, Synaptic Systems, 110 001), mouse VAMP2 (1:10000, Synaptic Systems, 104 211), rabbit
phospho-tau (Ser400;Thr403;Ser404) (1:1000, Cell Signaling, Beverly, MA, USA, 11837S). Secondary
antibodies against rabbit or mouse were conjugated either with IRDye (Licor) or HRP (Bio-Rad).
Immunohistochemistry
Mouse tissue samples for immunohistochemistry were prepared as described previously
(Rabe et al., 2012). In brief, for the preparation of cryosections, one half of the dissected whole
brain was fixed in 4% PFA for 4 hr at 4˚C and washed in PBS three times for 20 min each. Tissues
were immersed in 15% sucrose in PBS (1 hr), followed by 30% sucrose in PBS (overnight) and finally
in 50% tissue freezing medium (Tissue Tek, Leica) in 30% sucrose for 1 hr. Tissue was embedded in
the freezing medium, frozen at  20˚C and preserved at  80˚C until use.
For paraffin sections, whole brains of 12-month-old mice were fixed in 4% PFA overnight, washed
in PBS three times (20 min each) and subsequently immersed in 0.98% NaCl for 1 hr. The tissues
were then dehydrated in a stepwise series of ethanol dilutions (50%, 70%, 90%, 95%, 100%), cleared
in the ascending toluene/isopropanol dilution series and finally embedded in paraffin.
Immunostainings were performed on 10 mm thick cryo-sections. Sections were washed three
times in PBS and blocked in 10% FCS and 0.5% Triton-X100 in PBS for 60 min at room temperature.
Slides were incubated overnight with primary antibodies at 4˚C in blocking solution followed by
three washes in PBS (10 min each) and incubation with secondary antibodies (1: 750) for 60 min at
room temperature. Finally, sections were rinsed in PBS three times (10 min) and mounted with Vecta-
shield containing DAPI (Vector Laboratories, Burlingame, CA, USA, VEC-H-1500). Additional 8 mm
thick paraffin sections were used for IBA1/Hebp1 co-staining. Prior to the staining, paraffin sections
were hydrated through descending ethanol series and boiled for one minute in unmasking solution
(1:100 in water, Vector Laboratories).
The following primary antibodies were used for immunostainings: rabbit Hebp1 (1:100, Invitro-
gen, PA5-30609), rat Ctip2 (1:100, Abcam, ab18465), mouse GFAP (1:500, Synaptic Systems, 173
011), mouse GFAP (1:250, Sigma, C9205), guinea pig IBA-1 (1:100, Synaptic Systems, 134 004) and
guinea pig NeuN (1:200, Synaptic Systems, 266 004). Secondary antibodies against rabbit, mouse,
rat or guinea pig were conjugated either with Alexa488 or Alexa594 dye and were acquired from
Invitrogen, Carlsbad, CA, USA. Images were acquired by Leica TCS SP5 confocal laser scanning or
Zeiss Axio Vert.Z1 epifluorescent microscope.
Ab plaques were stained with thioflavin S (Santa Cruz, Dallas, TX, CAS 1326-12-1), as described
previously (Martinez Hernandez et al., 2018).
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Lentiviral transduction
For overexpression of Hebp1 in primary rat neurons, cDNA encoding full-length human Hebp1 (Ori-
gene, RC201873) was subcloned into the FUGW backbone (FUGW was a gift from David Baltimore,
Addgene plasmid #14883) using EcoRI and AgeI restriction enzymes. Empty FUGW vector was used
as a negative control for overexpression of EGFP. For production of lentiviral particles, HEK293 cells
were co-transfected with the FUGW-Hebp1/FUGW plasmid, and the helper plasmids psPax2 (a gift
from Didier Trono, Addgene plasmid #12260) and pCMV-VSV-G (a gift from Bob Weinberg, Addg-
ene, plasmid #8454) in a 2:1:1 ratio using Lipofectamine 2000. Medium was changed 6 hr after trans-
fection to DMEM supplemented with 2% FBS and 5 mM sodium butyrate. Culture supernatant was
harvested 24 hr and lentiviruses concentrated by ultracentrifugation via Amicon Ultra-15 filters (Milli-
pore, UFC910024). Concentrated lentiviruses were diluted to the final volume of 1 mL in DMEM/F12
medium, aliquoted, snap-frozen in liquid nitrogen and stored at  80˚C until use. Only lentivirus
preparations resulting in transduction rate of at least 90% (assessed by EGFP overexpression) were
used for experiments.
Live imaging of mitochondria
Primary rat hippocampal neurons were infected with lentiviruses overexpressing Hebp1-EGFP one
day after seeding and analyzed at DIV14. Briefly, cells were incubated with MitoTracker Red CMXRos
(Life Technologies, Rockford, IL, USA, M5712) in plating medium at final concentration of 10 nM for
minimum of 30 min. Cells were then imaged in Tyrode’s solution (10 mM Hepes, pH 7.3, 130 mM
NaCl, 4 mM KCl, 5 mM CaCl2, 1 mM MgCl2, 48 mM glucose) using Zeiss Observer 1 laser scanning
confocal microscope within 30 min period.
Identification of Hebp1 binding partners
Proteins interacting with Hebp1 were identified using co-immunoprecipitation coupled with mass
spectrometry in four independent biological experiments. Primary rat cortical neurons were infected
with lentiviruses expressing Hebp1-EGFP or EGFP one day after seeding. Neurons were lysed at
DIV14 with NP-40 lysis buffer. Lysates were clarified by centrifugation at 13,000  g for 10 min at 4˚
C. Hebp1-EGFP and EGFP were pulled down using GFP-trap according to manufacturer’s instruc-
tions. Beads were sequentially washed in lysis buffer containing descending concentrations of NP-40
(1%, 0.8%, 0.4%, 0.2%). Proteins were eluted by boiling the beads at 95˚C for 10 min in
1  NuPAGE LDS Sample Buffer and separated on 4–12% Bis-Tris NuPAGE gels (Thermo Fisher Sci-
entific, NP0342). Gels were stained with Coomassie solution overnight and destained in deionized
water for two days. Each lane was cut into six equal pieces and in-gel protein digestion was per-
formed as described previously (Shevchenko et al., 1996). Peptides extracted from each gel piece
were measured three times in independent technical repetitions.
The digested peptides were subjected to Q Exactive HF mass spectrometer (Thermo Fisher Sci-
entific) coupled with an Ultimate 3000 RSLC system (Dionex, USA). Peptides were separated on a
self-made capillary column (ReproSil-Pur 120 C18-AQ, 1.9 mm, Dr. Maisch GmbH, 300  0.075 mm;
C18 pre-column from Thermo Fisher (160454)) with a 5–42% linear gradient of increasing buffer B
(80% ACN, 0.08% FA) and decreasing buffer A (0.1% FA in water) for an overall run time of 58 min
at a constant flow rate of 300 nl/min. Separated peptides were ionized by electrospray ionization
source in a positive ion mode. Full-scan MS spectra were acquired in the range of 350–1600 m/z at
the resolution of 60,000 units. The top 30 most abundant precursors were selected for fragmenta-
tion in the collision cell with Higher-energy Collisional Dissociation with the normalized collision
energy of 30% and isolation window of 1.6 m/z. Max quant search was performed with the same
parameters used for brain proteome analysis.
Perseus software was used for downstream data analysis. The intensities of identified proteins
were log2 transformed and the missing values for identified proteins in each replicate were imputed
with the width of 0.3 and downshift of 1.8 in the total matrix mode. Log2 difference between
Hebp1-EGFP and EGFP samples was calculated for each identified protein and was averaged
between technical and biological replicates. Statistical significance of protein enrichment in each
sample was determined by one-sample t-test (p<0.05).
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Generation of Hebp1 knockout neurons by CRISPR/Cas9 system
sgRNAs (5’-CCCAGCATGGTGACGCCGTG-3’ (KO1); 5’-TGGCAGGTTCTAAGCACCGG-3’ (KO2); 5’-
CCGGTGCTTAGAACCTGCCCA-3’ (KO3)) targeting rat Hebp1 were designed using sgRNA
Designer (Broad Institute). The pLenti-CRISPR-Hebp1-KO vectors were generated by inserting the
sgRNAs into the LentiCRISPRv2 plasmid at the BsmBI site. The LentiCRISPRv2 plasmid is a gift from
Feng Zhang (Addgene, plasmid #52961). To obtain Hebp1 knockout neurons, cells were infected
individually with lentiviruses generated from the respective pLenti-CRISPR-Hebp1-KO constructs tar-
geting distinct rat sequences of Hebp1 (KO1, KO2 and KO3 sgRNAs) and subsequently tested for
Hebp1 expression by immunoblotting. Control neurons were infected with lentiviruses generated
from pLenti-CRISPR-Luc vector containing sgRNA targeting luciferase. Control, knockout and wild-
type neurons were utilized for further experiments.
Cell viability and apoptosis assays
Neurons were seeded on black 96-well plates (Corning Costar, 3603) at a density of 7  103 cells/
cm2. Cell toxicity was assessed using MultiTox-Glo reagent (Promega, G9270) according to the man-
ufacturer’s instructions. Briefly, cytotoxicity was measured by activity of dead-cell protease (lumines-
cent readout) and was normalized to cell viability measured by the activity of live-cell protease
(fluorescent readout) to account for discrepancies in cell number between the wells. Final cytotoxic-
ity values are presented as a fold change of corresponding vehicle control. Cells were treated with
10 mM hemin (Sigma, 51289), 25 mM tert-butyl-hydroperoxide (Sigma, 458139) or 1 mM staurospor-
ine (Santa Cruz, sc-3510). Hemin was always freshly prepared in accordance with a protocol pub-
lished previously (Atamna et al., 2015).
Apoptosis was assessed by measurement of caspase 3/7 activity using CellEvent Caspase-3/7
Green Detection Reagent (Sigma, C10723). Briefly, Caspase-3/7 Green Detection Reagent was
added simultaneously to cells exposed to hemin alone, 10 mM Ab42 oligomers alone or hemin
together with Ab42 oligomers. Cells were fixed and quantified 24 hr later. Ab42 oligomers (Abcam,
ab120301) were freshly prepared according to a published protocol (Ryan et al., 2013). Images
were acquired from five non-overlapping fields of each well with 20  objective, Zeiss Axio Observer
Z1 Microscope equipped with a motorized stage (DAPI, GFP and Cy3 channel). Cells positive for
Caspase-3/7 activity (GFP-positive) were quantified manually as a proportion of total number of cells
(DAPI-positive). Each experiment was performed at least in three independent biological repetitions
with three technical replicates for each condition.
Mitochondrial membrane potential was assayed with the Mitochondrial Membrane Potential
Assay kit (Cell Signaling, 13296) according to the manufacturer’s guidelines. Briefly, potentiometric
fluorescent TMRE dye (final concentration 200 nM) was added to neurons twenty-four hours after
hemin treatment. Fluorescence was measured 30 min after with Tecan reader (Infinite 200 PRO
series) plate reader using 550 nm and 615 nm excitation and emission filters, respectively.
Mitochondria isolation
Isolation of respective crude mitochondrial fractions from wild-type, Hebp1-deficient and control rat
hippocampal neurons was followed using a published protocol (Wieckowski et al., 2009). Briefly,
neurons were seeded at a density of 1  105 cells in T-25 flasks (Corning, C7046). After lentiviral
exposure for 7 days, neurons were washed with PBS prior to trypsin treatment for 2 min. Following
cell detachments, respective neurons were spun down and resulting cell pellets were resuspended in
PBS for another centrifugation. Corresponding cell pellets were then dissolved in a buffer (225 mM
mannitol, 75 mM sucrose, 0.1 mM EGTA and 30 mM Tris-HCl; pH, 7.4) and homogenized using a
Teflon pestle (Sigma, Singapore, P7734) with 20 strokes. Respective homogenates obtained were
spun down for supernatant collection. Further centrifugation of the supernatants at a higher speed
gave rise to respective cytosolic (supernatant) and mitochondrial portions (pellet), which were lysed
and subjected to protein analyses.
Statistical analysis
Proteomic data were analyzed as described in the section ‘Data processing and bioinformatics analy-
sis’. Statistical analysis of in vitro cell culture assays and immunoblotting data was performed in Prism
Yagensky et al. eLife 2019;8:e47498. DOI: https://doi.org/10.7554/eLife.47498 26 of 33
Research article Neuroscience
(Graph Pad). Applied statistical tests for each experiment are mentioned in the corresponding figure
legends.
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